MedPath

Vibrio cholerae CVD 103-HgR strain live antigen

Generic Name
Vibrio cholerae CVD 103-HgR strain live antigen
Brand Names
Vaxchora
Drug Type
Biotech
Chemical Formula
-
CAS Number
1704499-30-8
Unique Ingredient Identifier
V9G528E9E0
Background

Vibrio cholerae CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against Vibrio cholerae serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by Vibrio cholerae, which is gram-negative bacteria. Two serogroups of V. cholerae, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical.

The FDA approved the cholera vaccine containing Vibrio cholerae CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older.

Indication

Vibrio cholerae CVD 103-HgR strain live antigen is indicated for active oral immunization against infection caused by Vibrio cholerae serogroup O1 in patients between 2 and 64 years of age.

Associated Conditions
Cholera caused by Vibrio cholerae serogroup O1
Associated Therapies
-
tbsnews.net
·

Outsourcing clinical research as an avenue for export diversification in Bangladesh

Bangladesh has under-appreciated technical competence in agronomy and clinical research, exemplified by icddr,b's large-scale clinical trials. The global CRO market is rapidly growing, especially in Asia-Pacific, but Bangladesh lags in regulatory support for its CRO sector. With large population and developed human capital, Bangladesh could leverage clinical research outsourcing, facilitated by private sector innovation in harmonizing medical data and creating secure electronic health records. This could attract multinational CROs and pharmaceutical companies, positioning Bangladesh as a regional hub for clinical research and data aggregation.
© Copyright 2025. All Rights Reserved by MedPath